|Bid||32.13 x 2900|
|Ask||32.16 x 2900|
|Day's range||31.56 - 33.36|
|52-week range||19.51 - 73.72|
|Beta (5Y monthly)||1.81|
|PE ratio (TTM)||343.59|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Arrowhead Pharmaceuticals will present at Jefferies and Goldman Sachs healthcare conferences in June 2020
Investors in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) had a good week, as its shares rose 4.9% to close at...
Thank you for joining us today to discuss Arrowhead's results for its fiscal second quarter ended March 31, 2020. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, Chief Medical Officer who will discuss our clinical programs; Dr. Curt Bradshaw, our Chief Scientific Officer who will discuss our discovery, platform development and manufacturing efforts; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials.
It hasn't been the best quarter for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders, since the share price...
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. This report will, first...
Shareholders will be ecstatic, with their stake up 34% over the past week following Arrowhead Pharmaceuticals, Inc.'s...
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. First, this article will...
A look at the shareholders of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) can tell us which group is most powerful...
Anyone researching Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) might want to consider the historical volatility of...
Investing.com - Arrowhead Pharmaceuticals took a tumble midday Friday following a research downgrade that argued the stock is now fairly valued.